Sweroside

Sweroside at a Glance

Sweroside is a secoiridoid glycoside — a bitter, water-soluble molecule built on a ring-opened iridoid skeleton — and one of the most widely distributed secoiridoids in the Gentianales. It is a shared constituent of the classic bitter herbs: gentian and Swertia, cornelian cherry (Cornus officinalis) fruit, honeysuckle (Lonicera) and teasel root, where it co-occurs with siblings such as gentiopicroside, swertiamarin and amarogentin and contributes to their characteristic bitterness ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}.

As a molecule in its own right, sweroside has a broad but entirely preclinical pharmacology. Three signals stand out from the cell and rodent literature: hepatoprotection (across cholestatic, steatohepatitis and fatty-liver models), bone formation (osteogenic differentiation of osteoblasts and marrow stem cells), and wound healing (stimulating fibroblast collagen production) ^{1,3,6,10Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →Reference 10Öztürk N et al. · 2006Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblastsView study →}. Each is a coherent isolate story, and the bone and liver work even resolves to defined receptor and signalling pathways.

Two honesty caveats run through the whole page. There are no clinical trials of isolated sweroside: the human evidence for its sources is for the whole bitter herbs and their formulas, not the purified compound. And sweroside has very low oral bioavailability — around 0.31% in one rat study — so much of its in-vitro and high-dose potency overstates what an oral dose could deliver ^{11,12Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →Reference 12Sheng N et al. · 2014AnimalApplication of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of sweroside in ratsView study →}.

Sweroside Across the Bitter Herbs

The reason to treat sweroside as a single molecule rather than “a gentian compound” is that it appears across a whole cluster of unrelated bitter medicinal plants, and its research signals track that spread rather than any one herb.

Where it occurs. Sweroside is a defining secoiridoid of the Gentianaceae — it is one of the bitter principles of gentian root and Swertia chirayita (the “chirata” bitter tonic), alongside gentiopicroside, swertiamarin and the intensely bitter amarogentin ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}. But it reaches well beyond that family: it is a constituent of cornelian cherry (Cornus officinalis, shan zhu yu) fruit, of honeysuckle (Lonicera) and of teasel root (Dipsacus asper, xu duan) — which is where much of the bone-formation research actually sourced it ^{5Reference 5Wu QC et al. · 2020Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cellsView study →}. This wide occurrence is exactly what you would expect of a molecule sitting on the secologanin-derived branch of iridoid biosynthesis, the same pathway that produces its relatives oleuropein and harpagide from the shared precursor loganin.

What its isolate signals are. Three distinct threads recur, and they map loosely onto the traditional uses of its source herbs:

• Osteogenic / bone — sweroside promotes osteoblast and marrow-stem-cell differentiation, the thread behind teasel- and cornelian-cherry-based “bone-knitting” and “kidney-tonic” traditions ^{3,4,5Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 4Ding Y et al. · 2019Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiationView study →Reference 5Wu QC et al. · 2020Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cellsView study →}.
• Hepatoprotective — it protects hepatocytes across several liver-injury models, mirroring the bitter-tonic, “liver-clearing” role of gentian and Swertia ^{6,7,8,9Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →Reference 7Yang G et al. · 2020Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasomeView study →Reference 8Ding Y et al. · 2023AnimalSweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in miceView study →Reference 9Boateng AO et al. · 2025The hepatoprotective properties of gentiopicroside, sweroside, and swertiamarin against metabolic dysfunction-associated steatotic liver disease (MASLD)View study →}.
• Wound healing — it stimulates fibroblast collagen production and proliferation, consistent with gentian’s traditional topical wound use ^{10Reference 10Öztürk N et al. · 2006Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblastsView study →}.

The honest frame is that all of this is isolate work in cells and rodents. No human has been given purified sweroside in a trial; the plants themselves have the clinical and traditional footprint, and sweroside is one active among many bitter secoiridoids in each of them ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}.

What It's Used For

Sweroside’s evidence base is broad, internally consistent and entirely preclinical. The load-bearing caveat is the compound-page discipline: no human trials of the isolate, and very low oral bioavailability means in-vitro and high-dose rodent potency overreads what an oral dose delivers ^{1,11Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. There are no human isolate data, so scores stay modest by design.

01HepatoprotectivePromising46%Cholestasis, NASH and fatty-liver mouse models + hepatocyte studies ^{6,7,8,9Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →Reference 7Yang G et al. · 2020Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasomeView study →Reference 8Ding Y et al. · 2023AnimalSweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in miceView study →Reference 9Boateng AO et al. · 2025The hepatoprotective properties of gentiopicroside, sweroside, and swertiamarin against metabolic dysfunction-associated steatotic liver disease (MASLD)View study →}

02Osteogenic / boneShaky44%Osteoblast + marrow-stem-cell differentiation, defined receptor pathways, OVX bone model ^{3,4,5Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 4Ding Y et al. · 2019Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiationView study →Reference 5Wu QC et al. · 2020Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cellsView study →}

03Anti-inflammatoryShaky34%NLRP3/NF-κB suppression across liver, skin and cardiac models ^{7,13Reference 7Yang G et al. · 2020Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasomeView study →Reference 13Su H et al. · 2025Sweroside ameliorates IMQ-induced psoriasiform inflammation by inhibiting NLRP3/Caspase-1 mediated IL-1β elevationView study →}

04Wound healingShaky24%One gentian-secoiridoid fibroblast study (collagen, mitotic activity) ^{10Reference 10Öztürk N et al. · 2006Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblastsView study →}

Mechanisms

The reproduced core is an anti-inflammatory program (NLRP3, NF-κB) layered over two tissue-specific actions — an mTOR-linked osteogenic route and a mitochondrial/autophagic hepatoprotective route. The biosynthetic row is plant biochemistry, off the human-pharmacology axis.

Pharmacokinetics

Sweroside is a hydrophilic secoiridoid glucoside with very low oral bioavailability. A dedicated rat study estimated an absolute oral bioavailability of only ~0.31%, with the majority of the dose recovered unabsorbed in faeces ^{11Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}; a later LC-MS/MS study reported a somewhat higher figure (~11.9%) and a short plasma half-life of roughly 68–79 minutes across a 5–15 mg/kg range with linear kinetics ^{12Reference 12Sheng N et al. · 2014AnimalApplication of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of sweroside in ratsView study →}. Both agree the defining feature is poor and variable oral absorption, and the comprehensive reviews add rapid biotransformation (deglycosylation, reduction, glucuronidation) and restriction by efflux transporters (P-gp, MRP, BCRP) ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}. Notably, after intravenous dosing a substantial fraction (~31%) accumulated in bile — a hepatobiliary concentration the authors linked to sweroside’s hepatoprotective effects ^{11Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}. The practical consequence is the standard secoiridoid-glucoside caveat: micromolar in-vitro potency and high rodent doses substantially overstate an achievable oral human exposure, and sweroside is better understood as the poorly-absorbed marker of a whole-herb effect than as a stand-alone oral drug ^{1,11Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.

Clinical Trials

There are no controlled trials of isolated sweroside. Its human footprint is entirely indirect, through the whole bitter herbs — gentian, Swertia (chirata), cornelian cherry (shan zhu yu) and teasel root — and their multi-herb formulas, where sweroside is one of several actives and often serves as a quality-control marker rather than the tested agent ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

The split is clean and, on the mechanism side, favourable. Sweroside’s pharmacology is overwhelmingly the isolated molecule — the ANIT-cholestasis, NASH and fatty-liver liver studies ^{6,7,8Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →Reference 7Yang G et al. · 2020Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasomeView study →Reference 8Ding Y et al. · 2023AnimalSweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in miceView study →}, the MG-63/rat-osteoblast, marrow-stem-cell and MC3T3-E1 bone studies ^{3,4,5Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 4Ding Y et al. · 2019Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiationView study →Reference 5Wu QC et al. · 2020Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cellsView study →}, and the psoriasis anti-inflammatory work ^{13Reference 13Su H et al. · 2025Sweroside ameliorates IMQ-induced psoriasiform inflammation by inhibiting NLRP3/Caspase-1 mediated IL-1β elevationView study →} all test purified sweroside. That is a genuine attributional strength: these are sweroside’s own effects, not an extract’s. The weakness is translational, not attributional — very low oral bioavailability (~0.31% in rats) means isolate potency does not transfer cleanly to an achievable oral dose ^{11Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.

The human evidence inverts this: it belongs to the whole bitter herbs. Gentian, Swertia (chirata) and cornelian cherry are used as roots, fruits and inside formulas, where sweroside is one secoiridoid among several — co-occurring with gentiopicroside, swertiamarin and amarogentin — and is quantified for batch consistency rather than demonstrated as the active ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}. Even the wound-healing signal is really a property of the mixture of gentian secoiridoids, not sweroside in isolation ^{10Reference 10Öztürk N et al. · 2006Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblastsView study →}. So the correct reading is: strong isolate mechanism base + meaningful whole-herb tradition + no direct human isolate efficacy — the two are not interchangeable.

Its Role in Plants

In the plant, sweroside is a secoiridoid glycoside — a bitter, water-soluble defence compound stored inert as the glucoside and belonging to the same chemical class as the deterrent iridoids of many families. Its distinctive feature is biosynthetic: sweroside sits on the secologanin-derived branch of monoterpenoid metabolism. The route runs geraniol → … → loganin → secologanin, the hinge from which the secoiridoids — sweroside, gentiopicroside, swertiamarin and, further on, oleuropein — diverge from the monoterpene indole alkaloids ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}. The “seco” in secoiridoid marks the oxidative ring-opening of the cyclopentane ring of the parent iridoid, the step that distinguishes sweroside and its relatives from closed-ring iridoids such as harpagide.

Ecologically, this bitterness is the point: intensely bitter secoiridoids deter herbivores and are the chemical basis of the “bitter tonic” reputation of gentian and Swertia. As always, a molecule’s role in plant metabolism is plant biology, not human pharmacology, and does not predict what it does as a medicine.

Prevalence in Nature

Sweroside is a widespread secoiridoid across the Gentianales and neighbouring lineages. Its headline sources are the Gentianaceae — gentian (Gentiana spp.) root and Swertia (notably Swertia chirayita, the chirata bitter) — where it is one of the family’s characteristic bitter secoiridoids alongside gentiopicroside, swertiamarin and amarogentin ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}. Beyond that family it occurs in cornelian cherry (Cornus officinalis, shan zhu yu) fruit, honeysuckle (Lonicera) and teasel root (Dipsacus asper, xu duan), the last being the source in several of the bone studies ^{5Reference 5Wu QC et al. · 2020Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cellsView study →}. It is also reported from other Loganiaceae and Caprifoliaceae.

Absolute content is rarely reported as a clean % dry weight and varies widely with species, plant part, ripeness and processing, so a reliable cross-source concentration ranking does not yet exist here and is tracked as a gap rather than asserted ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}.

Discovery & Synthesis

Sweroside is a Gentianaceae secoiridoid long isolated from the bitter tonics of the family — Swertia (from which several of the “swer-” secoiridoids take their name, including swertiamarin) and gentian — and its structure was settled through twentieth-century natural-product chemistry as part of the broader elucidation of the iridoid and secoiridoid classes and their place on the secologanin-derived biosynthetic pathway ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}. Total synthesis of the sweroside/secoiridoid skeleton has been reported in the natural-product literature, but synthesis is not the supply route: research-grade sweroside is obtained by extraction from sweroside-rich plants — Swertia, gentian, cornelian cherry and teasel root — because the glucoside is relatively accessible there and its polar glycoside chemistry makes isolation far more practical than total synthesis ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}.

Patents: not yet researched.

Toxicity & Safety

Sweroside reads as a low-toxicity secoiridoid glycoside — it is a constituent of bitter herbs (gentian, Swertia/chirata, cornelian cherry) with long dietary and medicinal histories, and preclinical studies report no acute toxicity signal at the doses used, including hepatoprotective studies noting no observable toxicity in cells or animals and no cytotoxicity to osteoblasts at effective concentrations ^{1,3,6Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →}. The rating stays off “none” for evidentiary reasons: there is no comprehensive isolate toxicology package (no definitive LD50, genotoxicity or repeat-dose organ-toxicity dataset) for pure sweroside, and its very low oral bioavailability means real-world isolate exposure is limited ^{1,11Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.

Safety at a Glance

✅ Low / no toxicity

• A long-used bitter-herb secoiridoid. A constituent of gentian, Swertia (chirata) and cornelian cherry — herbs with long dietary/medicinal histories — with no acute toxicity signal in rodent studies ^{1,3Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →}.
• Real-world exposure is whole-herb and low. People meet sweroside as a bitter-herb constituent, not as a concentrated isolate, and its oral absorption is very poor (~0.31% in rats) ^{11Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.
• No comprehensive isolate toxicology. No definitive LD50, genotoxicity or repeat-dose package for the pure compound; safety is inferred from the whole herbs, not established for the molecule ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}.
• In-vitro potency overreads oral exposure. Very low bioavailability and rapid metabolism limit how far cell/high-dose findings translate ^{11,12Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →Reference 12Sheng N et al. · 2014AnimalApplication of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of sweroside in ratsView study →}.

Full Safety & Interactions Detail

Sweroside carries a low flag. It is a bitter secoiridoid of gentian, Swertia (chirata) and cornelian cherry (shan zhu yu) — plants with long dietary and medicinal use — and rodent efficacy studies report no acute toxicity signal at the doses used, with hepatoprotective work explicitly noting no observable cell or animal toxicity and bone studies noting no osteoblast cytotoxicity at effective concentrations ^{1,3,6Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 3Sun H et al. · 2013AnimalProtective effects of sweroside on human MG-63 cells and rat osteoblastsView study →Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →}.

The caveats are evidentiary rather than observed harms. First, there is no comprehensive isolate toxicology — no definitive LD50, genotoxicity or repeat-dose organ-toxicity dataset for pure sweroside — so its safety is inferred from the whole herbs, not demonstrated for the molecule ^{1Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →}.

Second, formal drug-interaction data are sparse: no specific CYP-inhibition profile is established, though its handling by efflux transporters (P-gp, MRP, BCRP) is documented, so interaction potential is largely uncharacterised rather than absent, and a scope note is warranted ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}.

Third, very low oral bioavailability (~0.31% in rats, with extensive faecal excretion and biliary concentration) both limits real-world isolate exposure and means high-dose or parenteral preclinical findings do not transfer cleanly to oral use ^{11Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}.

Reproductive note (prose only). No dedicated reproductive- or developmental-toxicity dataset exists for isolated sweroside. Any pregnancy or lactation caution around sweroside-containing herbs — gentian, Swertia, cornelian cherry, honeysuckle and teasel — belongs to the source herb and its actives, and is a decision made on the herb or product page where intake is decided, not on this molecule page.

Dosage

There is no established or recommended human dose for isolated sweroside — it has never been given to people as an isolate for therapy. Cited figures are preclinical research doses: micromolar concentrations in vitro, and roughly 30–250 mg/kg in rodents (for example 120 mg/kg in the cholestasis and ovariectomy models), often above achievable oral exposure given ~0.31% oral bioavailability ^{4,6,11Reference 4Ding Y et al. · 2019Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiationView study →Reference 6Yang QL et al. · 2016AnimalSweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responsesView study →Reference 11Luo YD et al. · 2009AnimalDetermination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretionView study →}. Human intake is indirect, through the whole bitter herbs — gentian and Swertia (chirata) roots, cornelian cherry (shan zhu yu) fruit, teasel root — and their multi-herb formulas, in which sweroside is one secoiridoid among several and is often quantified as a standardisation marker rather than dosed as a drug ^{1,2Reference 1Peng L et al. · 2025Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potentialView study →Reference 2Gan Z et al. · 2025ReviewSweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safetyView study →}. These are doses studied in research and are not a personal recommendation.

References

1. Peng L, Zuo M, Qiu T, Lan W, Wen Y, Ye XQ (2025). Sweroside: unveiling broad therapeutic potential — from mechanistic insights to clinical potential. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40799828/
2. Gan Z, Shi J, Liu W, Song Y, Xu X, Meng M, Meng X, Liu Y, Tang C, Zhang Y (2025). Sweroside: a comprehensive review of its biosynthesis, pharmacokinetics, pharmacology, and safety. Pharmacological Research. https://pubmed.ncbi.nlm.nih.gov/41151693/
3. Sun H, Li L, Zhang A, Zhang N, Lv H, Sun W, Wang X (2013). Protective effects of sweroside on human MG-63 cells and rat osteoblasts. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/23201331/
4. Ding Y, Jiang H, Meng B, Zhu B, Yu X, Xiang G (2019). Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiation. Journal of Cellular Biochemistry. https://pubmed.ncbi.nlm.nih.gov/31074104/
5. Wu QC, Tang XY, Dai ZQ, Dai Y, Xiao HH, Yao XS (2020). Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cells. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/32028183/
6. Yang QL, Yang F, Gong JT, Tang XW, Wang GY, Wang ZT, Yang L (2016). Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses. Acta Pharmacologica Sinica. https://pubmed.ncbi.nlm.nih.gov/27498779/
7. Yang G, Jang JH, Kim SW, Han SH, Ma KH, Jang JK, Kang HC, Cho YY, Lee HS, Lee JY (2020). Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/32316419/
8. Ding Y, Chen Y, Hu K, Yang Q, Li Y, Huang M (2023). Sweroside alleviates hepatic steatosis in part by activating AMPK/mTOR-mediated autophagy in mice. Journal of Cellular Biochemistry. https://pubmed.ncbi.nlm.nih.gov/37269482/
9. Boateng AO, Patel VB, Bligh SWA (2025). The hepatoprotective properties of gentiopicroside, sweroside, and swertiamarin against metabolic dysfunction-associated steatotic liver disease (MASLD). Biomolecules. https://pubmed.ncbi.nlm.nih.gov/40427619/
10. Öztürk N, Korkmaz S, Öztürk Y, Başer KHC (2006). Effects of gentiopicroside, sweroside and swertiamarine, secoiridoids from gentian (Gentiana lutea ssp. symphyandra), on cultured chicken embryonic fibroblasts. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/16557467/
11. Luo YD, Chen J, Cao J, Wen XD, Li P (2009). Determination of sweroside in rat plasma and bile for oral bioavailability and hepatobiliary excretion. Chemical & Pharmaceutical Bulletin (Tokyo). https://pubmed.ncbi.nlm.nih.gov/19122321/
12. Sheng N, Yuan L, Zhi X, Cui C, Zhang Z, Jia P, Zhang X, Zhang L, Wang X (2014). Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of sweroside in rats. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/25128643/
13. Su H, Yue H, Liu F, Sun Y, Liang S, Zheng X, Zhang Y, Zhang J, Wu J, Han L (2025). Sweroside ameliorates IMQ-induced psoriasiform inflammation by inhibiting NLRP3/Caspase-1 mediated IL-1β elevation. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/40010158/

View all 13 references▾